** Shares of drug developer CalciMedica CALC.O fall 84% to 84 cents premarket

** Co says an independent committee flagged safety concerns in the mid‑stage trial of Auxora for severe kidney injury, which could impact the organ's functioning

** Committee asked the co to review how patients were being enrolled

** No deaths were linked to the drug and no serious side effects required urgent FDA reporting, per co

** Co says it will review the data to decide if Auxora can be tested again; all enrolled patients will complete follow‑up

** Auxora had previously been tested in pancreatitis and COVID‑19 pneumonia without major safety issues, per co

** Shares up ~86% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))